Industry Insights
Latest in gene therapy and rare disease
Astellas unearths Dyno muscle disorder AAV capsid with $15M option agreement
Following a research collaboration established in 2021, Astellas Pharma has reached an agreement to license a Dyno Therapeutics gene therapy vehicle—an adeno-associated virus (AAV) capsid engineered f
As CGT Manufacturing Scales Up, Automation and Collaboration Become Essential
As cell and gene therapy developers face rising pressure to produce therapies faster and at lower cost, the industry is leaning on robotics, digital systems and partnerships to bridge the gap between
FDA’s 2027 Budget Proposes Permanent Rare Disease Vouchers, Easier Entry to Clinic
If the Trump administration’s proposal passes, the FDA’s budget will be more than $200 million bigger in 2027, with plans to launch new programs that expedite drug development, boost national security
Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout
Soleno finished 2025 with $190.4 million in net revenue from sales of Vykat. Neurocrine expects Vykat’s numbers to improve in coming years, since the drug is positioned as a foundational first-line th